Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders.Heart. 2016; 102: 790-795
- The risk of mortality in patients with psoriasis: results from a population-based study.Arch Dermatol. 2007; 143: 1493-1499
- Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.Arthritis Care Res (Hoboken). 2010; 62: 881-887
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.Ann Rheum Dis. 2012; 71: 1524-1529
- Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.BMJ. 2018; 361: k1036
- Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis.Best Pract Res Clin Rheumatol. 2018; 32: 369-389
- The link between inflammatory disorders and coronary heart disease: a look at recent studies and novel drugs in development.Curr Atheroscler Rep. 2016; 18: 3
- Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease.Curr Opin Cardiol. 2021; 36: 549-555
- Role of endothelial dysfunction in atherosclerosis.Circulation. 2004; 109: III-III27
- Vascular endothelium – Gatekeeper of vessel health.Atherosclerosis. 2016; 248: 97-109
- Endothelium.Arterioscler Thromb Vasc Biol. 2016; 36: e26-e31
- Inflammation and atherosclerosis.Annu Rev Pathol. 2006; 1: 297-329
- Inflammation in atherosclerosis.Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051
- Atherosclerosis.Nat Rev Dis Primers. 2019; 5: 56
- Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom.Br J Dermatol. 2010; 163: 586-592
- Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis.Br J Dermatol. 2008; 159: 895-902
- Real-world burden of comorbidities in US patients with psoriasis.J Am Acad Dermatol. 2017; 77: 287-292.e4
- Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.Arch Dermatol Res. 2006; 298: 321-328
- Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis.Metab Syndr Relat Disord. 2010; 8: 331-334
- Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis.Arch Dermatol. 2012; 148: 995-1000
- Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis.Semin Arthritis Rheum. 2007; 36: 203-209
- Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.Ann Rheum Dis. 2015; 74: 1118-1123
- Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.Ann Rheum Dis. 2016; 75: 341-347
- Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.Ann Rheum Dis. 2010; 69: 1920-1925
- Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non–rheumatoid arthritis patients.Arthritis Rheum. 2015; 67: 2004-2010
- Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis.J Invest Dermatol. 2016; 136: 1584-1591
- Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?.Curr Opin Rheumatol. 2019; 31: 285-292
- Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.Arthritis Care Res (Hoboken). 2011; 63: 522-529
- Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.Ann Rheum Dis. 2017; 76: 654-660
- Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.Ann Rheum Dis. 2007; 66: 670-675
- Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis.Arthritis Rheum. 2016; 68: 1337-1345
- Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.Arthritis Res Ther. 2008; 10: R30
- Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.Arthritis Res Ther. 2018; 20: 171
- Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.Circulation. 2002; 106: 2184-2187
- Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.Clin Rheumatol. 2010; 29: 763-770
- Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up.Rheumatology (Oxford). 2012; 51: 910-914
- No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.Rheumatology (Oxford). 2013; 52: 204-209
- Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.Arterioscler Thromb Vasc Biol. 2011; 31: 705-712
- Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions.Arthritis Rheum. 2020; 72: 1467-1475
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.J Am Acad Dermatol. 2019; 80: 1073-1113
- Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131
- From CRP to IL-6 to IL-1: moving upstream to identify novel targets for atheroprotection.Circ Res. 2016; 118: 145-156
- Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease.Circ Res. 2021; 128: 1728-1746
- Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J.(Available at:) (Accessed April 6, 2020)
- Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.JAMA. 2001; 286: 2107-2113
- Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.Drugs. 2018; 78: 929-940
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.Ann Rheum Dis. 2020; 79: 685-699
- Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.Mediators Inflamm. 2018; 2018: 2453265
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.Ann Rheum Dis. 2010; 69: 88-96
- Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.Ann Rheum Dis. 2017; 76: 1949-1952
- Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Arthritis Care Res. 2020; 72: 561-576
- Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).Eur Heart J. 2018; 39: 3499-3507
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.The Lancet. 2021; 397: 2060-2069
- From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?.Cardiovasc Res. 2021; 117: e138-e140
- Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.Atherosclerosis. 2018; 275: 107-114
- Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.Ann Rheum Dis. 2016; 75: 1813-1818
- The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease.Medicine (Baltimore). 2009; 88: 358-365
- Opposing roles of B lymphocyte subsets in atherosclerosis.Autoimmunity. 2017; 50: 52-56
- IL-23 promotes maintenance but not commitment to the Th17 lineage.J Immunol. 2008; 181: 5948-5955
- A Phase IV, Randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial).J Invest Dermatol. 2020; 140: 85-93.e2
- A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).J Invest Dermatol. 2020; 140: 1784-1793.e2
- Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis.Circ Cardiovasc Imaging. 2017; 10: e006283
- A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.J Invest Dermatol. 2012; 132: 304-314
- Association of ustekinumab and briakinumab with major adverse cardiovascular events.Dermatoendocrinol. 2012; 4: 320-323
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.Br J Dermatol. 2011; 164: 862-872
- An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.J Drugs Dermatol. 2012; 11: 300-312
- Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology.(Available at:) (Accessed July 22, 2021)
- Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.JAMA. 2011; 306: 864-871
- Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.J Eur Acad Dermatol Venereol. 2013; 27: 622-627
- IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.J Immunol. 2014; 193: 4344-4355
- Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease.Arterioscler Thromb Vasc Biol. 2014; 34: 2658-2668
- The IL-17A/IL-17RA axis plays a pro-atherogenic role via the regulation of aortic myeloid cell recruitment.Circ Res. 2012; 110: 675-687
- IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.Arterioscler Thromb Vasc Biol. 2015; 35: 258-264
- Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation.Nature. 2015; 523: 221-225
- Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content.Cardiovasc Res. 2018; 114: 158-167
- Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.J Am Acad Dermatol. 2018; 79: 345-352
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.Ann Rheum Dis. 2016; 75: 311-315
- New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.G Ital Dermatol Venereol. 2020; 155: 411-420
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.Semin Arthritis Rheum. 2016; 46: 261-271
- Embarking on a Career in Cardio-Rheumatology.J Am Coll Cardiol. 2020; 75: 1488-1492
- Collaborative cardio-rheumatology clinic for primary prevention of cardiovascular diseases - a descriptive study. ACR Meeting Abstracts.(Available at:) (Accessed February 17, 2021)
- Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.Meta-Analysis Ann Rheum Dis. 2019; 78: 1048-1054
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.Randomized Controlled Trial N Engl J Med. 2022; 386: 316-326
- Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.ACR Open Rheumatology. 2022; https://doi.org/10.1002/acr2.11479
- Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.Ann Rheum Dis. 2022; 81: 798-804
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
